Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27091119 | 0.86 | FAAH (0.33) | — | |
| SCHEMBL30875242 | 0.79 | TDP1 (0.48) | TDP1DRD2BRD4STK17BSTK17A | |
| SCHEMBL30875416 | 0.78 | FFAR1 (0.50) | TDP1DRD2PRMT5WDR77CYP3A4 | |
| SCHEMBL12435875 | 0.78 | FFAR1 (0.50) | TDP1DRD2PRMT5WDR77CYP3A4 | |
| SCHEMBL30875345 | 0.75 | TDP1 (0.41) | TDP1DRD2BRD4PRMT5WDR77 | |
| SCHEMBL30875430 | 0.74 | DRD2 (0.39) | TDP1DRD2BRD4PRMT5WDR77 | |
| SCHEMBL25433571 | 0.73 | PRMT5 (0.47) | DRD2PRMT5WDR77 | |
| SCHEMBL2878564 | 0.73 | DRD2 (0.42) | TDP1DRD2BRD4STK17BSTK17A | |
| SCHEMBL16169728 | 0.73 | FFAR1 (0.52) | TDP1DRD2PRMT5WDR77STK17B | |
| SCHEMBL21069375 | 0.73 | STK17B (0.44) | TDP1DRD2BRD4STK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | TDP1 246/4885DRD2 4688/4885BRD4 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.